InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals Inc. is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that act as preferential signaling ligands of the endogenous CB1 and CB2 receptors, as well as other receptor targets linked to human disease. These receptors are part of the endocannabinoid system, which is found throughout the human body and is responsible for many homeostatic functions. The company's research targets diseases with high unmet medical needs, and its candidates are patentable new chemical entities. It was incorporated in British Columbia in 1981 and adopted its current name in 2014.

The pipeline consists of three programs. INM-901 is a disease-modifying candidate for Alzheimer's disease. Its primary mechanism is the reduction of neuroinflammation, and it also impacts the PPAR signaling pathway. Preclinical studies in cell, animal, ex vivo and human brain organoid models showed neuroprotection, reduced inflammatory markers and improved cognitive and behavioral outcomes. A pre-IND meeting with the FDA is scheduled for the third quarter of calendar 2026, and the company targets an IND submission and Phase 1 trial start in 2027, subject to financing. INM-089 is a preclinical candidate for dry age-related macular degeneration, with data suggesting neuroprotective effects in the back of the eye. INM-755 (cannabinol) cream for Epidermolysis Bullosa has completed a Phase 2 trial, which showed a positive indication of enhanced anti-itch activity versus control cream. The company is open to strategic partnerships for INM-755 in EB and other itch-related skin conditions.

On March 4, 2026, the board approved the wind down of BayMedica, the company's only revenue-generating commercial operations segment. BayMedica had wound down all operating activities by June 30, 2026, and its remaining two employees departed on July 31, 2026. The remaining activities are preclinical development of the product candidates, and the company does not currently intend to devote significant resources to advancing them. Further development would require additional financing, and the company references a pending Merger. For its pharmaceutical candidates, it intends to submit new drug applications in most major jurisdictions, including the United States, alone or with development or commercial partners.

For manufacturing, the company can use chemical synthesis, biosynthesis, and a proprietary integrated approach called IntegraSyn, which gives it flexibility to select the most cost-effective method. As of September 1, 2026, it had six full-time employees, supplemented by consultants. Its principal mailing address is c/o Norton Rose Fulbright Canada LLP in Vancouver, British Columbia, and as of August 31, 2026 it no longer occupies executive office space.